Chronic back pain affects nearly everyone eventually, but some people develop debilitating spinal disc problems decades earlier than others due to genetic predisposition. This disparity has puzzled researchers seeking treatments that could prevent rather than merely manage degenerative disc disease before it becomes irreversible.
A targeted senolytic intervention using dasatinib (a leukemia drug) combined with quercetin (a plant flavonoid) successfully delayed disc degeneration in SM/J mice, a strain genetically programmed for early spinal breakdown. The combination therapy reduced key senescence markers including p19ARF and p21 proteins while diminishing the inflammatory senescence-associated secretory phenotype. Treatment preserved disc cell viability and prevented the characteristic tissue fibrosis that destroys the nucleus pulposus, the gel-like core that provides spinal cushioning. Transcriptomic analysis revealed the therapy specifically targeted cell cycle regulation and JNK signaling pathways across multiple disc tissues.
This research bridges laboratory senescence biology with a major clinical problem affecting millions. While senolytic therapies have shown promise against various age-related diseases, their application to spinal health represents a potentially transformative approach to preventing disability rather than treating it after onset. The identification of JUN pathway signaling as a therapeutic target was validated in human degenerated disc cells, suggesting the mouse findings may translate clinically. However, the leap from preventing genetically-driven degeneration in young mice to treating complex human disc disease involves significant unknowns around dosing, timing, and patient selection. This work nonetheless establishes proof-of-concept that cellular senescence drives disc degeneration and can be pharmacologically interrupted.
